Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases

de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl J Med. 2011;364:1995–2005.

Article  Google Scholar 

Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl J Med. 2012;367:1187–97.

CAS  Article  Google Scholar 

Halwani AS, Rasmussen KM, Patil V, Li CC, Yong CM, Burningham Z, et al. Real-world practice patterns in veterans with metastatic castration-resistant prostate cancer. Urologic Oncol. 2020;38:1 e–e10.

Google Scholar 

Khalaf DJ, Annala M, Taavitsainen S, Finch DL, Oja C, Vergidis J, et al. Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial. Lancet Oncol. 2019;20:1730–9.

CAS  Article  Google Scholar 

Izumi K, Mizokami A, Namiki M, Inoue S, Tanaka N, Yoshio Y, et al. Enzalutamide versus abiraterone as a first-line endocrine therapy for castration-resistant prostate cancer (ENABLE study for PCa): a study protocol for a multicenter randomized phase III trial. BMC Cancer. 2017;17:677.

Article  Google Scholar 

Wang X, Yang H, Hu X, Wang W, Yu X, Wang S, et al. Comparing the clinical efficacy and safety of abiraterone and enzalutamide in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis. J Oncol Pharm Pr. 2021;27:614–22.

CAS  Article  Google Scholar 

Tassinari D, Cherubini C, Roudnas B, Tamburini E, Drudi F, Bianchi E, et al. Treatment of metastatic, castration-resistant, docetaxel-resistant prostate cancer: a systematic review of literature with a network meta-analysis of randomized clinical Trials. Rev Recent Clin Trials. 2018;13:226–37.

CAS  Article  Google Scholar 

McCool R, Fleetwood K, Glanville J, Arber M, Goodall H, Naidoo S. Systematic review and network meta-analysis of treatments for chemotherapy-naive patients with Asymptomatic/Mildly symptomatic metastatic castration-resistant prostate cancer. Value Health: J Int Soc Pharmacoeconomics Outcomes Res. 2018;21:1259–68.

Article  Google Scholar 

Pal SK, Sartor O. Prostate cancer: The best fit for enzalutamide in metastatic prostate cancer. Nat Rev Clin Oncol. 2014;11:504–6.

CAS  Article  Google Scholar 

Chamie K, Daskivich TJ, Kwan L, Labo J, Dash A, Greenfield S, et al. Comorbidities, treatment and ensuing survival in men with prostate cancer. J Gen Intern Med. 2012;27:492–9.

Article  Google Scholar 

Bennett CL, Greenfield S, Aronow H, Ganz P, Vogelzang NJ, Elashoff RM. Patterns of care related to age of men with prostate cancer. Cancer 1991;67:2633–41.

CAS  Article  Google Scholar 

Matthes KL, Limam M, Pestoni G, Held L, Korol D, Rohrmann S. Impact of comorbidities at diagnosis on prostate cancer treatment and survival. J cancer Res Clin Oncol. 2018;144:707–15.

Article  Google Scholar 

Lu-Yao G, Nikita N, Keith SW, Nightingale G, Gandhi K, Hegarty SE, et al. Mortality and hospitalization risk following oral androgen signaling inhibitors among men with advanced prostate cancer by pre-existing cardiovascular comorbidities. Eur Urol. 2020;77:158–66.

CAS  Article  Google Scholar 

Soleimani M, Zou K, Sunderland K, Struss W, Eigl BJ, Nappi L, et al. Effectiveness of first-line abiraterone versus enzalutamide among patients >/=80 years of age with metastatic castration-resistant prostate cancer: A retrospective propensity score-weighted comparative cohort study. Eur J Cancer. 2021;152:215–22.

CAS  Article  Google Scholar 

Hu J, Aprikian AG, Vanhuyse M, Dragomir A. Comparative cardiovascular safety of novel hormonal agents in metastatic castration-resistant prostate cancer using real-world data. Clin Genitourin Cancer. 2022;20:17–24.

Article  Google Scholar 

Riekhof F, Luo S, Cheranda N, Govindan S, Sanfilippo KM, Schoen MW. Hospitalizations and common infections among veterans treated for metastatic prostate cancer. J Clin Oncol. 2022;40(6_suppl):92.

Article  Google Scholar 

Scailteux LM, Despas F, Balusson F, Campillo-Gimenez B, Mathieu R, Vincendeau S, et al. Hospitalization for adverse events under abiraterone or enzalutamide exposure in real-world setting: A French population-based study on prostate cancer patients. Br J Clin Pharm. 2022;88:336–46.

Article  Google Scholar 

Sun L, Parikh RB, Hubbard RA, Cashy J, Takvorian SU, Vaughn DJ, et al. Assessment and management of cardiovascular risk factors among US veterans with prostate cancer. JAMA Netw Open. 2021;4:e210070.

Article  Google Scholar 

Tagawa ST, Ramaswamy K, Huang A, Mardekian J, Schultz NM, Wang L, et al. Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate. Prostate Cancer Prostatic Dis. 2021;24:1032–40.

CAS  Article  Google Scholar 

Scailteux LM, Campillo-Gimenez B, Kerbrat S, Despas F, Mathieu R, Vincendeau S, et al. Overall survival among chemotherapy-naive patients with castration-resistant prostate cancer under abiraterone versus enzalutamide: A Direct Comparison Based on a 2014-2018 French Population Study (the SPEAR Cohort). Am J Epidemiol. 2021;190:413–22.

Article  Google Scholar 

Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377:352–60.

CAS  Article  Google Scholar 

Romano PS, Roos LL, Jollis JG. Presentation adapting a clinical comorbidity index for use with ICD-9-CM administrative data: Differing perspectives. J Clin Epidemiol. 1993;46:1075–9.

CAS  Article  Google Scholar 

Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi J-C, et al. Coding Algorithms for Defining Comorbidities in ICD-9-CM and ICD-10 Administrative Data. Med Care. 2005;43:1130–9.

Article  Google Scholar 

Flaig TW, Potluri RC, Ng Y, Todd MB, Mehra M, Higano CS. Disease and treatment characteristics of men diagnosed with metastatic hormone-sensitive prostate cancer in real Life: Analysis from a commercial claims database. Clin Genitourin cancer. 2017;15:273–9.e1.

Article  Google Scholar 

Riviere P, Luterstein E, Kumar A, Vitzthum LK, Deka R, Sarkar RR, et al. Survival of African American and non-Hispanic white men with prostate cancer in an equal-access health care system. Cancer 2020;126:1683–90.

CAS  Article  Google Scholar 

Halabi S, Ou SS, Vogelzang NJ, Small EJ. Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancer. Cancer 2007;110:1478–84.

Article  Google Scholar 

Lee HY, Chen HL, Teoh JY, Chen TC, Hao SY, Tsai HY, et al. Abiraterone and enzalutamide had different adverse effects on the cardiovascular system: a systematic review with pairwise and network meta-analyses. Prostate Cancer Prostatic Dis. 2021;24:244–52.

CAS  Article  Google Scholar 

Tsao PA, Estes JP, Griggs JJ, Smith DC, Caram MEV. Cardiovascular and Metabolic Toxicity of Abiraterone in Castration-resistant Prostate Cancer: Post-marketing Experience. Clin Genitourin cancer. 2019;17:e592–e601.

Article  Google Scholar 

Kulkarni AA, Rubin N, Tholkes A, Shah S, Ryan CJ, Lutsey PL, et al. Risk for stroke and myocardial infarction with abiraterone versus enzalutamide in metastatic prostate cancer patients. ESMO Open. 2021;6:100261.

CAS  Article  Google Scholar 

Cone EB, Reese S, Marchese M, Nabi J, Kilbridge KL, Trinh Q-D. Association of abiraterone and higher odds of cardiac complications compared to enzalutamide. J Clin Oncol. 2020;38:70.

Article  Google Scholar 

Karantanos T, Karanika S, Gignac G. Uncontrolled diabetes predicts poor response to novel antiandrogens. Endocr Relat Cancer. 2016;23:691–8.

CAS  Article  Google Scholar 

George DJ, Ramaswamy K, Huang A, Russell D, Mardekian J, Schultz NM, et al. Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2022;25:524–30.

Alvarado LC. Do evolutionary life-history trade-offs influence prostate cancer risk? a review of population variation in testosterone levels and prostate cancer disparities. Evol Appl. 2013;6:117–33.

Article  Google Scholar 

Halabi S, Dutta S, Tangen CM, Rosenthal M, Petrylak DP, Thompson IM Jr, et al. Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel. J Clin Oncol. 2019;37:403–10.

CAS  Article  Google Scholar 

Heiden BT, Eaton DB, Jr., Chang SH, Yan Y, Baumann AA, Schoen MW, et al. Racial Disparities in the Surgical Treatment of Clinical Stage I Non-Small Cell Lung Cancer Among Veterans. Chest. 2022.

Schoen MW, Luo S, Carson KR, Sanfilippo KM. Survival and Treatment of Black Patients with Chronic Lymphocytic Leukemia in the Veterans Health Affairs. Blood 2018;132:4847.

Article  Google Scholar 

Fillmore NR, Yellapragada SV, Ifeorah C, Mehta A, Cirstea D, White PS, et al. With equal access, African American patients have superior survival compared to white patients with multiple myeloma: a VA study. Blood 2019;133:2615–8.

Article  Google Scholar 

Martini A, Shah QN, Waingankar N, Sfakianos JP, Tsao CK, Necchi A, et al. The obesity paradox in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2022;25:472–8.

Vidal AC, Howard LE, de Hoedt A, Kane CJ, Terris MK, Aronson WJ, et al. Obese patients with castration-resistant prostate cancer may be at a lower risk of all-cause mortality: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int. 2018;122:76–82.

Article  Google Scholar 

Vidal AC, Oyekunle T, Howard LE, De Hoedt AM, Kane CJ, Terris MK, et al. Obesity, race, and long-term prostate cancer outcomes. Cancer 2020;126:3733–41.

CAS  Article  Google Scholar 

George DJ, Sartor O, Miller K, Saad F, Tombal B, Kalinovsky J, et al. Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States. Clin Genitourin cancer. 2020;18:284–94.

Article  Google Scholar 

Leuva H, Sigel K, Zhou M, Wilkerson J, Aggen DH, Park YA, et al. A novel approach to assess real-world efficacy of cancer therapy in metastatic prostate cancer. Analysis of national data on Veterans treated with abiraterone and enzalutamide. Semin Oncol. 2019;46:351–61.

CAS  Article  Google Scholar 

de Wit R, de Bono J, Sternberg CN, Fizazi K, Tombal B, Wulfing C, et al. Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. N. Engl J Med. 2019;381:2506–18.

Article  Google Scholar 

Fizazi K, Tran N, Fein LE, Matsubara N, Rodríguez Antolín A, Alekseev BY, et al. LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer. Journal of Clinical Oncology. 2017;35 (18_suppl):LBA3-LBA.

留言 (0)

沒有登入
gif